Therefore, a stepwise mode to select for gene mutations in NSCLC is suggested: first for KRAS, second for EGFR, EML4-ALK translocation, and then for concomitant EML4-ALK fusion and EGFR mutations. The gene discussed is EML4; the disease is non-small cell lung carcinoma.